Creatine gummies, NAD+ longevity and beetroot nitric oxide are the categories compounding fastest this year. Here is what the numbers actually say — and how to enter each one without betting the business on a trend.
TL;DR
Short answer: Three categories are compounding fastest in 2026: creatine, where the gummy sub-segment is growing near 26% a year; NAD+ and longevity precursors, projected near $447M with roughly 29% growth; and beetroot-driven nitric oxide, a category worth about $1.1B growing close to 10.6%. Enter each with a stock formula at a low entry tier rather than paying for custom development.
Most private label brands fail not because the product is bad, but because the category was flat. A good formula in a shrinking niche is still a hard sell; an average formula in a rising category gets pulled along by demand you did not have to create. So before choosing a formula, read the direction of the category — then choose the format and the entry tier that let you test it cheaply.
| Category | Momentum | Best-fit buyer | Natural formats |
|---|---|---|---|
| Creatine | Supplement market ~$1.7B in 2026; gummy sub-segment ~26% CAGR | Sports, strength and everyday performance | Gummies, powder |
| NAD+ & longevity | ~$447M in 2026, growing about 29% | Healthy-aging and longevity shoppers | Capsules |
| Beetroot / nitric oxide | Nitric oxide ~$1.1B, growing about 10.6% | Pre-workout and circulation-minded adults | Softgels, capsules, gummies, powder |
Figures are drawn from published market research for 2025–2026 and are indicative, not a forecast guarantee. Verify current numbers before you build a business case on them.
Creatine has crossed over from the gym to everyday health, and the gummy format removes the two friction points that held casual buyers back: scooping powder and swallowing tablets. That is exactly why the gummy sub-segment is outgrowing the powder base it came from, compounding at roughly 26% a year.
Why it converts
Chewable, travel-friendly and easy to bundle — the format sells on convenience, not on a new claim.
Watch-outs
Dose per gummy is the constraint — high-dose expectations can force a multi-gummy serving. Confirm the labelling math early.
NAD+ precursor supplements are one of the strongest-growing categories in healthy aging, with sales projected near $447M in 2026 and growth rates still in the high twenties. It fits the same shopper who already buys collagen, magnesium and omega-3 for the long game.
The asterisk that matters
The category is real, but the ingredient form decides your risk. And the US position has moved twice since 2022: the FDA excluded the best-known NAD+ precursor in 2022, then reversed that in a September 2025 letter. That is exactly why no two-year-old answer is safe to rely on. Lock down the exact ingredient form and its current regulatory position in your destination market before you write a label or brief a designer. We cover the forms, the dose arithmetic and the compliance timeline in detail in our NAD+ manufacturing guide.
Beetroot is the tortoise of the three. It is less hyped than NAD+, but nitric oxide — the benefit consumers actually shop for — is a category worth around $1.1B and still growing close to 10.6% a year, and it has an unusually wide format range: softgels, capsules, gummies and powder all sell.
What are the fastest-growing supplement categories in 2026?
Three stand out: creatine (especially creatine gummies), NAD+ / longevity precursors, and beetroot-driven nitric oxide. Creatine supplements are forecast around $1.7B in 2026 with gummies compounding near 26% a year; NAD+ precursor sales are projected near $447M at about 29% growth; nitric oxide sits around $1.1B growing close to 10.6%.
Why are creatine gummies growing so fast?
Creatine has moved from a hardcore gym ingredient to a mainstream daily-health one, and gummies remove the friction of scooping powder and swallowing pills. The format converts on convenience and impulse, which is why gummy SKUs are outgrowing the powder base they came from.
Is NAD+ a good category for a new supplement brand?
It depends on the ingredient form. The category is growing fast and fits the longevity buyer, but regulatory status moves — the FDA excluded the best-known NAD+ precursor in 2022 and reinstated it in a September 2025 letter, so any published answer is a snapshot. Confirm the exact form and its current status in your market before committing.
Which format should I choose for these categories?
Match the format to the buyer. Creatine and beetroot work well as gummies or powder for sports audiences; NAD+ and beetroot also suit capsules and softgels for daily-wellness and longevity shoppers. The same active can support several SKUs, so validate one format first.
Can I enter these categories with a low minimum order?
Yes. Stock formulations on these actives are typically available from low entry tiers, so you can test demand before paying for custom development. Always check the SKU's own published tier rather than assuming from the category.
How do I avoid compliance risk in a trending category?
Trending categories attract claim-heavy marketing. Keep to structure-function language, add the standard FDA disclaimer, avoid disease claims, and confirm ingredient forms and dosages on paper (specification and COA) before you publish a label.
We now stock creatine gummies, an NAD+ / resveratrol capsule and a full beetroot nitric oxide line — all with real entry tiers on the Products Hub. Send an RFQ and we will recommend the format that fits your buyer.